We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSENS.L Regulatory News (SENS)

  • There is currently no data for SENS

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Launch of CVm-Health app in the US

19 May 2020 16:00

RNS Number : 3871N
Sensyne Health PLC
19 May 2020
 

 

Clinical AI leader Sensyne Health launches CVm-Health™ 'Good Neighbor' app in the United States with support from Microsoft and Cognizant

 

New COVID-19 web-based app helps people record their health status and symptoms and do the same for family and friends

 

Highlights:

· CVm-Health is a free, easy to use web-based software application now available in the US

· Enables the recording of health conditions, symptoms, vital signs and medications, creating a health diary that can be shared with healthcare professionals

· Empowers people to help family or friends who do not have access to the internet monitor their health

· The CVm-Health app was developed with support from Microsoft and Cognizant and is part of a broader strategy by Sensyne Health to provide a platform that enables the delivery of care to patients remotely

 

Oxford, U.K. May 19,2020: Sensyne Health plc (LSE: SENS) ("Sensyne" or the "Company" or the "Group"), the Clinical AI technology company, today announces the US launch of its web-based COVID-19 focused software application called CVm-Health - the 'Good Neighbor' app. CVm-Health was successfully rolled out in the UK in April 2020.

 

CVm-Health US app - launched today

Today's launch of CVm-Health in the US coincides with the start of the Microsoft Build conference, where the app will be highlighted https://youtu.be/FIOPM6TiOmg 

 

The app is free to use for anyone in the US and provides a secure way for individuals to manage their health by recording their vital signs daily and any COVID-19 related symptoms.

 

The app also enables individuals to help family and friends who are digitally disconnected and at risk from coronavirus to monitor their health. In 2019 the Pew Research Center found that 10% of all Americans and 27% of Americans over 65 don't use the internet, and many of these people are in higher-risk categories for COVID-19.

 

Subject to individuals consent, data generated by the application will be de-identified and analyzed using sophisticated machine learning techniques to derive insights that will be made available for medical research into the prevention, diagnosis and treatment of COVID-19.

The app was developed with the support of Cognizant and Microsoft. Sensyne announced its partnership with Cognizant in October 2019 to accelerate the development of its applications specifically for the US market. Microsoft is Sensyne's chosen provider of world-class IT infrastructure services, including its Azure® suite of cloud services, which enable Sensyne's clinical applications to be scaled globally.

 

Lord (Paul) Drayson, CEO of Sensyne Health, said:

"We wanted to provide an app that helped everyone to record and self-monitor their symptoms and take control of their own health, as well as helping others."

 

 

CVm-Health is available to use at www.CVm-Health.com

 

-ENDS-

 

 

For more information please contact:

Sensyne Health (www.sensynehealth.com)

+44 (0) 330 058 1845

Lord (Paul) Drayson PhD FREng, Chief Executive Officer

Michael Norris, Interim Chief Financial Officer

 

Peel Hunt LLP (Nominated Adviser and Joint Broker)

 

+ 44 (0) 20 7418 8900

Dr Christopher Golden

James Steel

Oliver Jackson

Liberum (Joint Broker)

+ 44 (0) 20 3100 2000

Bidhi Bhoma

Euan Brown

Consilium Strategic Communications

+44 (0) 7780 600290

Mary-Jane Elliott

Sukaina Virji

Melissa Gardiner

sensynehealth@consilium-comms.com

Consilium Strategic Communications US

001 617-680-1088

Paul Kidwell

kidwell@consilium-comms.com

 

About Sensyne Health

 

Sensyne Health plc is a clinical AI company that works in partnership with global healthcare organizations to improve patient care and accelerate the discovery and development of new medicines. Sensyne Health is listed on the AIM Market of the London Stock Exchange (SENS.L).

 

For more information, please visit: www.sensynehealth.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
MSCKKCBBQBKDQPD
Date   Source Headline
3rd Nov 20213:00 pmBUSForm 8.3 - SENS LN
3rd Nov 20212:10 pmRNSForm 8.3 - Sensyne Health plc
3rd Nov 20211:54 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 20211:10 pmRNSForm 8.3 - Sensyne Health Plc
3rd Nov 202112:58 pmGNWInvesco Ltd.: Form 8 (OPD) - Sensyne Health PLC
3rd Nov 202112:08 pmRNSHolding(s) in Company
3rd Nov 202112:00 pmRNSForm 8.5 (EPT/RI) - Sensyne Health Plc
3rd Nov 20219:51 amRNSForm 8.5 (EPT/RI)
3rd Nov 20218:23 amRNSForm 8.3 - Sensyne Health Plc
2nd Nov 20213:02 pmGNWForm 8.3 - Octopus Investments - Sensyne Health plc
2nd Nov 20217:00 amRNSStrategic update, FSP triggered by potential MBO
29th Oct 20215:04 pmRNSResults of Annual General Meeting
21st Oct 20217:00 amRNSMagnifEye European regulatory certification
15th Oct 20217:00 amRNSSensyne and OMNY Health Sign Teaming Agreement
6th Oct 20217:00 amRNSHoldings in Company
6th Oct 20217:00 amRNSAnnual Report and Accounts
4th Oct 20212:05 pmRNSSecond Price Monitoring Extn
4th Oct 20212:00 pmRNSPrice Monitoring Extension
1st Oct 20217:00 amRNSSensyne Health 2021 Financial Results
24th Sep 20217:00 amRNSNotice of Preliminary Results
9th Sep 20217:00 amRNSLaunch of SENSIGHT data analytics platform
2nd Sep 20217:00 amRNSSensyne & GOSH partner in child disease research
19th Aug 20217:00 amRNSSensyne SRA With Sentara Healthcare
10th Aug 20217:00 amRNSSensyne announces AI drug discovery project
2nd Aug 20217:01 amRNSBoard Change
2nd Aug 20217:00 amRNSSensyne dataset reaches 60m patients
22nd Jul 20217:00 amRNSAppointment of Chief Scientific Officer
19th Jul 20217:00 amRNSSensyne Health Provides Strategic Update
18th Jun 20217:00 amRNSNED Appointment
17th Jun 20213:02 pmRNSHolding(s) in Company
1st Jun 20217:00 amRNSMagnifEye Production Contract with UK DHSC
28th May 20212:24 pmRNSShare Option Award
27th May 20217:00 amRNSTrading Update
25th May 20211:13 pmRNSHolding(s) in Company
24th May 20217:00 amRNSSRA with Colorado Center for Personalized Medicine
21st May 20219:14 amRNSPharmaceutical collaboration
21st May 20217:00 amRNSSensyne signs SRA with St. Luke’s
7th May 202111:12 amRNSHolding(s) in Company
7th May 20217:00 amRNSMagnifEye Gains MHRA Approval
6th May 20217:00 amRNSValue Creation Plan Award
30th Apr 20217:00 amRNSSensyne SRA with Royal Devon and Exeter NHS Trust
16th Apr 20217:00 amRNSIssue of Shares and Total Voting Rights
12th Mar 20217:00 amRNSAgreement with the UK DHSC
1st Mar 20217:00 amRNSBoard Changes
1st Mar 20217:00 amRNSSYNE-COV Achieves UK Regulatory Approval
10th Feb 20212:06 pmRNSSecond Price Monitoring Extn
10th Feb 20212:00 pmRNSPrice Monitoring Extension
9th Feb 20217:48 amRNSSensyne licenses MagnifEye technology to Excalibur
5th Feb 20212:57 pmRNSHoldings in Company
5th Feb 20212:24 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.